u/DrKevinTran

Posting this because the framework is genuinely useful regardless of whether you watch the interview, and I think this community will get value from it.

Background on the guest: 30 years as a U.S. intelligence analyst (Russia/weapons programs background). Currently a National Board Certified Health and Wellness Coach, Functional Medicine Certified Coach, and ReCODE certified (Bredesen protocol for cognitive decline reversal). She's APOE4 3/4. Found out via 23andMe over a decade ago, before most physicians could explain what the variant meant.

The part I want to share is her method for reading medical research. As an analyst, she had to learn to do this fast and at scale. It boils down to two filters applied in sequence, then ranking studies by both filters.

Filter 1: Bias. Who funded the study, and what's their incentive structure? An industry-funded study on its own product isn't automatically wrong, but it's weighted differently than an independent academic study. She also notes that you can usually tell without reading the conclusion (the framing in the introduction and the choice of comparators reveals the bias).

Filter 2: Methodology robustness. RCT with hundreds of subjects? Observational case series with twelve people? Mechanistic in-vitro work? All can be useful. They live at different certainty levels and should never be cited interchangeably.

Then she ranks: high-trust independent + robust = high weight. Industry-funded + small n = noted with caveat. Nothing gets ignored, nothing gets blindly trusted. It's intelligence tradecraft applied to PubMed.

Other things we covered if anyone wants to dig deeper:

• Her brain fog > Mediterranean keto arc (A1C 5.7 → 5.4 in months)
• The Fasting Mimicking Diet (Longo's protocol, now being used as adjunct in oncology trials)
• Her current daily stack after 13 years of iteration (methylated B's, omegas in phospholipid form, urolithin A, creatine, vitamin D)
• Practical tips for avoiding keto flu

I spent the last few weeks going deep on the Davidson BROADWAY APOE substudy (just published in JPAD in late 2025) and made a ~31-minute video walking through the full evidence chain. Wanted to share the core findings here in text first, and the video link at the bottom if useful.

The one-paragraph version

In a pre-specified substudy of BROADWAY (the Phase 3 lipid trial of obicetrapib, n=2,530, published in NEJM earlier in 2025), 1,535 participants had baseline + 12-month p-tau217 measured along with APOE genotyping. In APOE4/4 homozygotes, obicetrapib produced a 7.81% mean decrease in p-tau217 vs a 12.67% increase on placebo.
That's a 20.48% placebo-adjusted treatment difference (p=0.010). Effect scaled with APOE risk: smallest in non-carriers, largest in E4/E4. Five biomarkers moved favorably in E4/E4 (p-tau217, Abeta42:40, p-tau217/Abeta ratio, GFAP, NfL), placebo-adjusted benefits ranging 13.67–22.65%.

The Davidson quote I keep coming back to (verbatim, discussion section):

>"These findings represent the first demonstration of an oral intervention capable of reducing both beta-amyloid and tau pathology biomarkers in ApoE4 carriers, offering a potential preventive strategy for this high-risk population who currently have no effective prevention options."

Why I think this finding isn't noise

1. Pre-specified, not fished. APOE genotyping and biomarker collection were declared up front.
2. Effect scales with genetic risk, opposite of the anti-amyloid monoclonal pattern where APOE4 carriers get worse efficacy + more ARIA.
3. Mechanistically coherent. CETP inhibition raises HDL particles and the ApoE riding on them. Preclinical (Poliakova & Wellington 2025) and genetic data (Schmidt MR, Alz Res Ther 2024 — APOE4-stratified OR 0.61 for LBD vs OR 0.89 in non-carriers, interaction p=5.81×10⁻⁴) both predicted an APOE4-concentrated benefit before this paper came out.
4. Five biomarkers moved, not one. Including GFAP (neuroinflammation: -6.39% obi vs +8.85% placebo in E4/E4) and NfL (neurodegeneration). Hard to explain as a statistical fluke across five independent markers.
5. Independent confirming analysis. A larger overlapping 1,727-patient analysis (Davidson et al., AAIC 2025 conference abstract, published in Alz & Dementia) showed concordant results — p-tau217 stabilized in APOE4 carriers (0% vs 5.7%, p=0.03), p-tau217/Abeta ratio 2.1% vs 10.2% (p=0.005). Same clinical program, so not independent evidence — but it's internal consistency.

What this does NOT prove

• Biomarker =/= cognitive outcome. Nobody has measured MMSE or CDR-SB on obicetrapib. p-tau217 is the cleanest blood surrogate for AD pathology we have, but "surrogate" is the operative word.
• No dedicated AD prevention RCT exists. That trial would need to happen post-PREVAIL.
• APOE4/4 subgroup is small within the 1,535. Needs replication outside the BROADWAY/BROOKLYN program.
• Obicetrapib is NOT FDA-approved. Can't get it at a pharmacy.
• PREVAIL (n=9,541, CV outcomes primary endpoint) reads out late 2026. Until PREVAIL, there is no confirmed cardiovascular mortality benefit either. The pooled BROADWAY+BROOKLYN MACE signal (3.9% vs 5.0%; HR 0.77; CI 0.54-1.11; p=0.16) is exploratory.

Other pieces of the evidence map worth knowing

• BROADWAY LDL-C primary endpoint: -29.9% (95% CI -32.1 to -27.8) on top of max statins at day 84 (Nicholls 2025, NEJM).
• BROOKLYN HeFH trial (Nissen 2025, Nature Medicine): placebo-adjusted Lp(a) -45.9%, ApoB -24.4%, non-HDL -34.5%, HDL +138.7%. No BP signal, 7.6% discontinuation vs 14.4% placebo.
• 2025 meta-analysis (Araujo et al., Am J Prev Cardiol), 7 RCTs / 3,381 patients: pooled LDL-C -37.21%, Lp(a) -37.16%, ApoB -24.65%. New-onset diabetes reduced (RR 0.88; p=0.01). No significant differences in adverse events.
• Mechanistic plausibility: Poliakova & Wellington 2025 (J Cardiol Cardiovasc Sci) — "In mice... HDL levels are highly associated with CAA and... peripheral injection of synthetic HDL particles stimulates clearance of both Abeta42 and Abeta40 from the brain."
• Older genetics: Barzilai 2006 (Neurology), Ashkenazi centenarians — CETP VV genotype (naturally lower CETP) associated with preserved MMSE >25. Cache County 2015 (Lythgoe et al.) — "0.6-point decrease per year in the rate of cognitive decline for each additional valine (p < 0.011)" — but CETP I405V "not associated with LOAD status" (calibration — trajectory, not diagnosis).

What I'd actually do with this information in 2026

1. Get a baseline advanced lipid panel if you don't have one: ApoB, Lp(a), particle count. You want numbers now so you can see movement later.
2. p-tau217 is now available as a commercial blood test. If you're APOE4/4 and want a baseline, it's a reasonable lab to have on file.
3. Track PREVAIL's late-2026 readout. A positive outcomes trial likely triggers FDA filing, which likely triggers a dedicated AD prevention trial in APOE4 carriers. You'd want to be a candidate.
4. In the meantime, fundamentals (exercise, sleep, MIND/Med diet, BP, glucose, Lp(a) awareness) are the levers that are actually available to you right now.

Primary sources:

• Davidson 2025 (JPAD): https://pmc.ncbi.nlm.nih.gov/articles/PMC12811769/
• Nicholls 2025 BROADWAY (NEJM): https://www.nejm.org/doi/full/10.1056/NEJMoa2415820
• Nissen 2025 BROOKLYN (Nature Medicine): https://www.nature.com/articles/s41591-025-04179-4
• Schmidt 2024 MR (Alz Res Ther): https://pmc.ncbi.nlm.nih.gov/articles/PMC11481778/
• Araujo 2025 meta-analysis: https://pmc.ncbi.nlm.nih.gov/articles/PMC12528909/

Quick context: I'm an APOE4/4 carrier and Doctor of Pharmacy. I run a community of APOE4 carriers and host a monthly podcast with Dr. Grant Fraser, a board-certified anti-aging physician who specializes in APOE4 patients and is an APOE4 carrier himself.

Posting this here specifically for APOE4 carriers in the Attia audience (and for anyone tracking aggressive biomarker targets).

Dr. Fraser's clinical framework is built around the idea that "normal" reference ranges are built on statistical distributions of an unhealthy general population, which makes them unreliable as health targets, and even less reliable for a population (APOE4 carriers) with a 2-12x increase in neurodegeneration risk. That's the same conceptual frame Attia uses around lipids and visceral fat.

A few takeaways I thought this sub would find useful:

Homocysteine — target 6-7 (treat >8)

The "normal" lab range climbs from 14.5 (age 60) to 21.3 (age 80+) depending on the lab. Dr. Fraser argues those age-adjusted normals are exactly the problem — they describe the statistical center of an aging population, not optimal physiology. He treats anything above 8.

Tiered protocol:

1. Methylfolate 500-2000 mcg + methylcobalamin 500-2000 mcg + B6 25-50 mg (recheck at 4-6 weeks)
2. If not moving: add TMG/betaine 500-2000 mg + riboflavin 10-20 mg (relevant for MTHFR carriers)
3. If still elevated and serum folate is paradoxically >24: switch to folinic acid 800 mcg, which bypasses the folate receptor entirely

He also makes the point that B12 testing without MMA is incomplete. MMA tells you if B12 is functionally active. A normal B12 with elevated MMA still warrants intervention.

Omega-3 Index — target 10-12% for APOE4 (vs. >8% for general population)

The APOE4-specific concern is MFSD2A, the transporter that moves DHA across the blood-brain barrier. APOE4 impairs it. So even if peripheral omega-3 index looks adequate, brain DHA delivery may be compromised.

Practical implications:

• Cap supplements at 1g EPA+DHA daily (dose-related afib risk above that, primarily in older patients)
• Fish-form omega-3 appears to reach the brain more reliably than supplement-form (probably because phospholipid carriers get cleaved in digestion)
• Two servings of wild king salmon per week delivers ~6g EPA+DHA from food
• Dr. Fraser hedges his own stack across krill oil + LPC-DHA + fish to cover multiple delivery mechanisms

Other bits worth noting:

• Standard NAC likely doesn't cross the BBB. NAC ethyl ester does, dosed at 1/20th of standard NAC (around 100 mg/day for brain-targeted use).
• Low-dose doxycycline as an MMP-9 inhibitor (20-30mg BID, sub-antimicrobial) is an emerging hypothesis for blood-brain-barrier protection in APOE4. Animal data is hopeful, human data is thin, but worth tracking if you follow the BBB-deterioration literature.

This is Part 1 of a 4-part series. Parts 2-3 cover inflammation/oxidation markers and hormones. Part 4 covers the new p-tau217-class blood assays for AD pathology detection, which I think is the most important diagnostic development for APOE4 carriers in the last decade.